Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt

Author:

Abd El-Halim Jackleen AzerORCID,Gewaifel Gihan Ismael,Darwish Eman Ahmed Fawzy,Ramadan Ahmed Maher,ElSisi Gihan Hamdy

Abstract

Abstract Introduction Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committee of treatment and control of viral hepatitis has already offered a high-quality service for the diagnosis and treatment of CHB on a free basis. The current study aims to estimate the health care resources utilization and the annual direct medical cost associated with different clinical stages of CHB-related disease in Egypt. Methodology The data was retrieved through record review for three months in the General Administration of Hepatitis Viruses Control, Egypt. Then, the data was extrapolated to the population level by multiplying the prevalence in Egypt with a focus on the productive age groups (25–59 years). Results The cost and utilization of different health care resources increase with disease progression. The total annual direct medical costs due to CHB in Egypt is 21.3 L.E. Billion (4.7 Int$ billion/year) for the management of estimated 1,420,700 CHB patients. The direct medical costs among the productive age group (25–59 years) constitute more than half of the total cost (57%). The highest disease burden is encountered among (25–29 years) age group; 2.695 L.E. billion (0.59 Int$ billion/year). Despite liver transplantation phase being associated with the highest annual cost/patient, the number of patients in this stage is the lowest. Then, it only constitutes 0.04% of the disease direct medical cost in the country. The chronic hepatitis clinical stage constitutes 57.26% of the disease direct medical cost in Egypt’s working age group. Conclusion Strengthening the preventive and control measures is mandatory to alleviate the disease’s direct medical costs. Close monitoring of the chronic hepatitis stage is mandatory to prevent disease progression. Enhancement of vaccination efforts will lower the disease prevalence and its cost. The universal health insurance system which is gradually implemented in Egypt nowadays will be a cornerstone in relieving the economic stresses by allowing more access to high-quality health care services.

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Reference31 articles.

1. World Health Organization. Hepatitis B fact sheet. Updated 27 July 2020. Available from: [https://www.who.int/news‐room/factsheets/detail/hepatitis‐b]. Accessed July 2021.

2. Lu J, Xu A, Wang J, Zhang L, Song L, Li R, Zhang S, Zhuang G, Lu M (2013) Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 13:37

3. Alavian S, Hajarizadeh B, Asl M, Kabir A, Lankarani K (2008) Hepatitis B virus infection in Iran: a systematic review. Hepat Mon (4):281–294 Available from: https://sites.kowsarpub.com/hepatmon/articles/70005.html

4. Yeekian C, Pitisuttithum P (2014) Costs of chronic hepatitis B patients in a developing country. J Nurs Educ Pract 4(9):128

5. Zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y et al (2016) Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat 23:202–210

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3